Document:

EX-10.1

 Exhibit 10.1 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

AMENDMENT NO. 3 TO LOAN AND SECURITY AGREEMENT 

This AMENDMENT NO. 3 TO LOAN AND SECURITY AGREEMENT (this “Amendment”), is entered into this 24th day of September,
2014, by and among AVEO PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“HTGC Inc.”), HERCULES CAPITAL FUNDING TRUST
2012-1, a statutory trust created and existing under the laws of the State of Delaware (“Trust”), and HERCULES TECHNOLOGY III, L.P., a Delaware limited partnership (“Hercules III”, together with HTGC Inc.
and Trust collectively referred to as the “Lender”). 
 WHEREAS, Borrower and Lender are parties to a certain Loan
and Security Agreement, dated as of May 28, 2010, as amended by that certain Amendment No. 1 to Loan and Security Agreement, dated as of December 21, 2011, and as further amended by that certain Amendment No. 2 to Loan and
Security Agreement, dated as of March 31, 2012 (as the same may from time to time be further amended, modified or supplemented in accordance with its terms, the “Loan Agreement”); and 

WHEREAS, in accordance with Section 11.3 of the Loan Agreement, Borrower and Lender desire to amend the Loan Agreement as provided
herein. 
 NOW THEREFORE, in consideration of the mutual agreements contained in the Loan Agreement and herein and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1.
Defined Terms. Terms not otherwise defined herein which are defined in the Loan Agreement shall have the same respective meanings herein as therein. 

2. Amendments to Loan Agreement. Subject to the satisfaction of the conditions set forth in Section 4 of this Amendment,
the Loan Agreement is hereby amended as follows: 
 (a) The Loan Agreement shall be amended by (i) deleting
“and” at the end of Recital C, (ii) changing “.” to “;” at the end of Recital D; and (iii) inserting the following new provisions to appear as Recitals E, F, and G thereof: 

“E. Borrower has requested that Lender make available to Borrower one (1) loan (the “2014 Term Loan
Advance”) in an aggregate principal amount of Ten Million and No/100 Dollars ($10,000,000) (the “Maximum 2014 Term Loan Amount”); 

F. Lender is willing to make the 2014 Term Loan Advance on the terms and conditions set forth in this Agreement; and 

G. Lender has consented to that certain Third Amendment to Lease and Lease Termination Agreement by and between the Borrower
and BMR-650 E KENDALL B LLC dated as of September 24, 2014, pursuant to the terms of that certain Consent to Loan and Security Agreement by and among the Lender and the Borrower dated as of September 24, 2014.” 

(b) The Loan Agreement shall be amended by inserting the following new definitions to appear alphabetically in Section 1.1
(Definitions and Rules of Construction) thereof: 
 “2010 End of Term Charge” has the meaning given to it in
Section 2.5 hereof. 
 “2014 Closing Date” September 24, 2014. 

“2014 End of Term Charge” has the meaning given to it in Section 2.5 hereof. 

  
 1 

 “2014 Extension Date” has the meaning given to it in the definition of 2014
Term Loan Amortization Date. 
 “2014 Facility Fee” means One Hundred Eight Thousand Seventy-Two Dollars and
Seventy-Two Cents ($108,072.72). 
 “2014 Term Loan Advance” has the meaning given to it in Recital E hereof. 

“2014 Term Loan Amortization Date” means November 1, 2015; provided, however, that if the Interest Only Period Extension
Event No. 1 occurs prior to such date, at the request of Borrower, the 2014 Term Loan Amortization Date shall be May 1, 2016 (the “2014 Extension Date”); and provided further, however, that if the Interest Only Period
Extension Event No. 2 occurs prior to the 2014 Extension Date, at the request of Borrower, the 2014 Term Loan Amortization Date shall be November 1, 2016. 

“2014 Term Loan Interest Rate” means the greater of (i) 11.90% and (ii) 11.90% plus the Prime Rate; provided,
however, that in no event shall the 2014 Term Loan Interest Rate exceed 15.0%. 
 “2014 Term Loan Maturity Date” means
January 1, 2018. 
 “2014 Warrants” shall mean the warrants to purchase shares of common stock of the Borrower
issued to the Lender by the Borrower on the 2014 Closing Date. 
 “Financial Covenant Termination Event” means
(a) delivery by Borrower to Lender, after the 2014 Closing Date, of evidence satisfactory to Lender in Lender’s reasonable discretion, that Borrower has received favorable data (i.e., achieving the primary endpoint with respect to the
trials set forth in (i) and (ii) of this definition) with respect to its (i) Ficlatuzumab phase 2 clinical study, and (ii) AV-380 phase 1 clinical study, or (b) Lender’s election, in Lender’s sole and absolute
discretion, to discontinue testing of the financial covenant set forth in Section 7.20. 
 “Interest Only Period Extension
Event No. 1” means confirmation by Lender, in Lender’s reasonable discretion, that Borrower has received, after the 2014 Closing Date, but on or prior to November 1, 2015, net upfront unrestricted cash payments in an amount
equal to or greater than [**] Dollars ($[**]), deposited in Deposit Accounts subject to an Account Control Agreement(s) in favor of Lender, resulting from corporate development partnerships [**]. For the avoidance of doubt, the calculation of
“net upfront unrestricted cash payments” as used in this definition shall include license payments received from any such corporate development partnership [**]. 

“Interest Only Period Extension Event No. 2” means confirmation by Lender, in Lender’s reasonable discretion, after
the occurrence of the Interest Only Period Extension Event No. 1, but on or prior to the 2014 Extension Date, that the following milestones have been achieved: (a) Borrower’s first (1st) patient has been dosed in a phase 1
clinical study of its AV-380 product, and (b) Borrower has received unrestricted and unencumbered net cash proceeds in an amount equal to or greater than [**] Dollars ($[**]), deposited in Deposit Accounts subject to an Account Control
Agreement(s) in favor of Lender, resulting from corporate development partnerships and/or from the issuance and sale by Borrower of its equity securities. For the avoidance of doubt, the calculation of “unrestricted and unencumbered net cash
proceeds” as used in this definition shall include any payments received from any such corporate development partnership. 

  
 2 

 “Liquidity Ratio” is the ratio of (a) the sum of all of Borrower’s
unrestricted and unencumbered cash and cash equivalents having maturities of not more than ninety (90) days from the date of determination, in each case only to the extent maintained in Deposit Accounts and/or accounts holding Investment
Property that are subject to an Account Control Agreement(s) in favor of Lender, to (b) the aggregate amount of all outstanding Secured Obligations of Borrower to Lender under the 2014 Term Loan Advance. For the avoidance of doubt, the
calculation of the Liquidity Ratio shall not take into account any cash or cash equivalents of MSC Subsidiary. 
 “Maximum 2014 Term
Loan Amount” has the meaning given to it in Recital E hereof. 
 (c) The following definitions appearing in
Section 1.1 thereof are amended in their entirety and replaced with the following: 
 “Advance(s)” means a Term Loan
Advance and/or a 2014 Term Loan Advance, as applicable. 
 “Note(s)” means a promissory note or promissory notes to
evidence Lender’s Loans. 
 “Prime Rate” means for any day (a) with respect to the Term Loan Advance, the prime
rate as reported in The Wall Street Journal minus 4.75%, or (b) with respect to the 2014 Term Loan Advance, the prime rate as reported in The Wall Street Journal minus 5.25%. 

“Term Loan” means any term loan advanced under Section 2.1 of this Agreement. 

“Term Loan Advance” means any Term Loan funds advanced under Section 2.1 of this Agreement. 

“Term Loan Amortization Date” means January 1, 2015. 

“Term Loan Maturity Date” means December 1, 2015. 

“Warrant” means, collectively, all warrants to purchase shares of capital stock of the Borrower issued to Lender by the
Borrower (including, without limitation, the New Warrants and the 2014 Warrants). 
 (d) Notwithstanding Section 2.1(d)
of the Loan Agreement, provided no Event of Default has occurred or is continuing, the scheduled principal payments due on October 1, 2014, November 1, 2014, and December 1, 2014 with respect to the Term Loan (the
“Deferred Payments”) shall be deferred (not waived). Borrower shall continue to make monthly payments of interest as set forth in Section 2.1(d) of the Loan Agreement. The aggregate balance of the Term Loan, including the
Deferred Payments, outstanding on the day immediately preceding the Term Loan Amortization Date, shall re-amortize and commencing on the Term Loan Amortization Date, and continuing on the first
(1st) business day of each month thereafter, Borrower shall make equal monthly installments of principal and interest (mortgage style) based upon an amortization schedule equal to twelve
(12) consecutive months. Borrower’s final payment due on the Term Loan Maturity Date shall include all outstanding principal and accrued and unpaid interest under the Term Loan and all other outstanding Secured Obligations with respect to
the Term Loan. For the abundance of caution, any principal received by Lender prior to the 2014 Closing Date shall not be returned and shall be deemed applied toward such scheduled principal payment. 

  
 3 

 (e) The Loan Agreement is amended by inserting immediately after Section 2.1
the following new provision to appear as Section 2.1.1 (2014 Term Loan) thereof: 
 “2.1.1 2014 Term Loan. 

(a) Advance. Subject to the terms and conditions of this Agreement, Lender will make, and Borrower agrees to draw, the
2014 Term Loan Advance in an amount of the Maximum 2014 Term Loan Amount on the 2014 Closing Date. 
 (b) Advance
Request. To obtain the 2014 Term Loan Advance, Borrower shall complete, sign and deliver to Lender an Advance Request. Lender shall fund the 2014 Term Loan Advance in the manner requested by the Advance Request provided that each of the
conditions precedent to such 2014 Term Loan Advance is satisfied as of the requested Advance Date. 
 (c) Interest.
The principal balance of the 2014 Term Loan Advance shall bear interest thereon from such Advance Date at the 2014 Term Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days
elapsed. The 2014 Term Loan Interest Rate will float and change on the day the Prime Rate changes from time to time. 
 (d)
Payment. Prior to the 2014 Term Loan Amortization Date, Borrower will pay interest on the 2014 Term Loan Advance on the first (1st) business day of each month, beginning the month after the applicable Advance Date. Commencing on the 2014
Term Loan Amortization Date, and continuing on the first (1st) business day of each month thereafter, Borrower shall repay the aggregate principal balance of the 2014 Term Loan Advance that is outstanding on the day immediately preceding the
2014 Term Loan Amortization Date in equal monthly installments of principal and interest (mortgage style) based upon an amortization schedule equal to thirty (30) consecutive months. After any change in the effective rate hereunder, Lender
shall recalculate future payments of principal and interest to fully amortize the outstanding principal amount over the remaining scheduled monthly payments hereunder prior to the 2014 Term Loan Maturity Date (and Lender will provide subsequent
notice to Borrower of any such recalculations). The entire 2014 Term Loan Advance unpaid principal balance and all accrued but unpaid interest hereunder, and all other Secured Obligations with respect to the 2014 Term Loan Advance, shall be due and
payable on the 2014 Term Loan Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the Borrower’s
account as authorized on the ACH Authorization on each payment date of all periodic obligations payable to Lender under the 2014 Term Loan Advance. Once repaid, the 2014 Term Loan Advance or any portion thereof may not be reborrowed.” 

(f) The last two sentences set forth in Section 2.3 (Default Interest) are amended in their entirety and replaced with the
following: 
 “In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations,
including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.1(c) or 2.1.1(c), as applicable, plus five percent (5%) per annum. In the event any
interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.1(c), 2.1.1(c), or Section 2.3, as applicable.” 

(g) Section 2.4 (Prepayment) is amended in its entirety and replaced with the following: 

“2.4 Prepayment. At its option upon at least seven (7) business days prior notice to Lender, Borrower may prepay all, but not
less than all, of the outstanding 2014 Term Loan Advance by paying the entire principal balance, all accrued and unpaid interest, all unpaid Lender’s fees and expenses accrued to the date of the prepayment (including the 2014 End of Term
Charge), together with a prepayment charge equal to the following 

  
 4 

 
percentage of the principal 2014 Term Loan Advance amount being prepaid: if such 2014 Term Loan Advance is prepaid in any of the first twelve (12) months following the 2014 Closing Date,
three percent (3.00%); after twelve (12) months following the 2014 Closing Date but prior to twenty four (24) months following the 2014 Closing Date, two percent (2.00%); and thereafter but prior to the 2014 Term Loan Maturity Date, one
percent (1.00%) (each, a “Prepayment Charge”). Borrower agrees that the Prepayment Charge is a reasonable calculation of Lender’s lost profits in view of the difficulties and impracticality of determining actual damages
resulting from an early repayment of the 2014 Term Loan Advance. Upon the occurrence of a Change in Control, Borrower shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and all unpaid Lender’s
fees and out-of-pocket expenses under the Loan Documents accrued to the date of the repayment (including the 2014 End of Term Charge) together with the applicable Prepayment Charge.” 

(h) Section 2.5 (End of Term Charge) is amended in its entirety and replaced with the following: 

“2.5 End of Term Charges. On the earliest to occur of (i) June 1, 2014, (ii) the date that Borrower prepays the
outstanding Secured Obligations, or (iii) the date that the Secured Obligations become due and payable, Borrower shall pay Lender a charge equal to One Million Two Hundred Thirty Seven Thousand Five Hundred Dollars ($1,237,500) (the
“2010 End of Term Charge”). Notwithstanding the required payment date of such charge, the 2010 End of Term Charge shall have been deemed to have been earned by Lender as of the Closing Date. Borrower has paid such 2010 End of Term
Charge in full as of the 2014 Closing Date. In addition, on the earliest to occur of (i) the 2014 Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding Secured Obligations, or (iii) the date that the Secured
Obligations become due and payable, Borrower shall pay Lender a charge equal to Five Hundred Forty Thousand Three Hundred Sixty-Three Dollars and Sixty Cents ($540,363.60) (the “2014 End of Term Charge”). Notwithstanding the
required payment date of such charge, the 2014 End of Term Charge shall have been deemed to have been earned by Lender as of the 2014 Closing Date.” 

(i) The Loan Agreement is amended by inserting the following new provision to appear as Section 2.8 (Notes) thereof: 

“2.8 Notes. If so requested by Lender by written notice to Borrower, then Borrower shall execute and deliver to Lender (and/or, if
applicable and if so specified in such notice, to any person who is an assignee of Lender pursuant to Section 11.13) (promptly after the Borrower’s receipt of such notice) a Note or Notes in the form of Exhibit B-3 to evidence 2014 Term
Loan Advances.” 
 (j) Section 3 (Security Interests) of the Loan Agreement is amended by deleting subsection
(ii)(D) of the proviso in the first sentence of Section 3.1 in its entirety and replacing it with the following: 
 “(D) cash held
in money market account no. 1892029636 at Comerica Bank in an amount not to exceed $2,997,418.00 plus accrued interest to secure certain letters of credit (the “Comerica Letters of Credit”) and” 

(k) Section 5.3 (Consents) is amended by deleting each reference to “New Warrants” therein and inserting in lieu
thereof “Warrants”. 
 (l) Section 7.1 (Financial Reports) is amended by deleting subsection (d) in its
entirety and replacing it with the following: 
 “(d) promptly after the sending or filing thereof, as the case may be, copies of any
proxy statements, financial statements or reports that Borrower has made available to holders of its capital stock and copies of any regular, periodic and special reports or registration statements that Borrower files with the Securities and
Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange;” 

  
 5 

 (m) Section 7.1 (Financial Reports) is amended by deleting subsection
(f) in its entirety and replacing it with the following: 
 “(f) budgets, operating plans, updates on clinical
trials, and other financial information reasonably requested by Lender.” 
 (n) The Loan Agreement is amended by
inserting the following new provision to appear as Section 7.20 (Financial Covenant) thereof: 
 “7.20 Financial Covenant.
Borrower shall maintain at all times, commencing with the 2014 Closing Date and continuing through the date on which the Financial Covenant Termination Event occurs, a Liquidity Ratio equal to or greater than 1.25:1.00.” 

(o) Section 9.2 (Covenants) is amended in its entirety and replaced with the following: 

“9.2 Covenants. Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, the
Notes, or any of the other Loan Documents, and (a) with respect to a default under any covenant under this Agreement (other than under Sections 6.1, 7.5, 7.6, 7.7, 7.8, 7.9, 7.13, 7.18, 7.19, or 7.20) such default continues for more than ten
(10) business days after the earlier of the date on which (i) Lender has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect to a default under any of Sections 6.1,
7.5, 7.6, 7.7, 7.8, 7.9, 7.13, 7.18, 7.19, or 7.20, the occurrence of such default; or” 
 (p) Exhibit A (Advance
Request) is amended in its entirety and replaced with the Advance Request appearing as Schedule 1 attached hereto. 

(q) The Loan Agreement shall be amended by inserting a new Exhibit B-3 (2014 Term Loan Advance Promissory Note)
appearing as Schedule 2 attached hereto. 
 (r) Exhibit F (Compliance Certificate) is amended in its entirety
and replaced with the Compliance Certificate appearing as Schedule 3 attached hereto. 
 3. Conditions to
Effectiveness. Lender and Borrower agree that this Amendment shall become effective upon the satisfaction of the following conditions precedent, each in form and substance satisfactory to Lender: 

(a) Lender shall have received a fully-executed counterpart of this Amendment signed by Borrower; 

(b) Lender shall have received certified resolutions of Borrower’s board of directors evidencing approval of this
Amendment; 
 (c) Lender shall have received a legal opinion (authority/enforceability) from Borrower’s counsel dated as
of the 2014 Closing Date; 
 (d) Lender shall have received a duly executed Perfection Certificate from Borrower dated as of
the 2014 Closing Date; 

  
 6 

 (e) Borrower shall have paid to Lender, for the account of Lender, the 2014
Facility Fee; and 
 (f) Lender shall have received payment for all fees and expenses incurred by Lender in connection with
this Amendment, including, but not limited to, all legal fees and expenses. 
 4. Post-Closing Condition. Notwithstanding
anything to the contrary set forth in the Loan Agreement, on or before the date that is thirty (30) business days after the 2014 Closing Date, Borrower shall deliver to Lender endorsements to Borrower’s liability and property policies in
accordance with Section 6.2 of the Loan Agreement. 
 5. Representations and Warranties. The Borrower hereby represents
and warrants to Lender as follows: 
 (a) Representations and Warranties in the Agreement. The representations and
warranties of Borrower set forth in Section 5 of the Loan Agreement are true and correct in all material respects on and as of the date hereof with the same effect as though made on and as of such date, except to the extent such representations
and warranties expressly relate to an earlier date. 
 (b) Authority, Etc. The execution and delivery by Borrower of
this Amendment and the performance by Borrower of all of its agreements and obligations under the Loan Agreement and the other Loan Documents, as amended hereby, are within the corporate authority of Borrower and have been duly authorized by all
necessary corporate action on the part of Borrower. With respect to Borrower, the execution and delivery by Borrower of this Amendment does not and will not require any registration with, consent or approval of, or notice to any Person (including
any governmental authority). 
 (c) Enforceability of Obligations. This Amendment, the Loan Agreement and the other
Loan Documents, as amended hereby, constitute the legal, valid and binding obligations of Borrower enforceable against Borrower in accordance with their terms, except as enforceability is limited by bankruptcy, insolvency, reorganization,
moratorium, general equitable principles or other laws relating to or affecting generally the enforcement of, creditors’ rights and except to the extent that availability of the remedy of specific performance or injunctive relief is subject to
the discretion of the court before which any proceeding therefor may be brought. 
 (d) No Default. Before and after
giving effect to this Amendment (i) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default, and (ii) no event that has had or could reasonably be expected
to have a Material Adverse Effect has occurred and is continuing. 
 (e) Event of Default. By its signature below,
Borrower hereby agrees that it shall constitute an Event of Default if any representation or warranty made herein should be false or misleading in any material respect when made. 

6. Reaffirmations. Except as expressly provided in this Amendment, all of the terms and conditions of the Loan Agreement and the
other Loan Documents remain in full force and effect. Nothing contained in this Amendment shall in any way prejudice, impair or effect any rights or remedies of Lender under the Loan Agreement and the other Loan Documents. Except as specifically
amended hereby, Borrower hereby ratifies, confirms, and reaffirms all covenants contained in the Loan Agreement and the other Loan Documents. The Loan Agreement, together with this Amendment, shall be read and construed as a single agreement. All
references in the Loan Documents to the Loan Agreement or any other Loan Document shall hereafter refer to the Loan Agreement or any other Loan Document as amended hereby. 

7. Execution in Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed an
original, but which together shall constitute one instrument. 

  
 7 

 8. Miscellaneous.  

(a) THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF CALIFORNIA,
EXCLUDING CONFLICT OF LAWS PRINCIPLES THAT WOULD CAUSE THE APPLICATION OF LAWS OF ANY OTHER JURISDICTION. 
 (b) The captions
in this Amendment are for convenience of reference only and shall not define or limit the provisions hereof. 
 (c) This
Amendment expresses the entire understanding of the parties with respect to the transactions contemplated hereby. No prior negotiations or discussions shall limit, modify, or otherwise affect the provisions hereof. 

(d) Any determination that any provision of this Amendment or any application hereof is invalid, illegal or unenforceable in
any respect and in any instance shall not affect the validity, legality, or enforceability of such provision in any other instance, or the validity, legality or enforceability of any other provisions of this Amendment. 

[Remainder of this page intentionally left blank] 

  
 8 

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Amendment as of the day and
year first above written. 
  

			
	BORROWER:
	
	AVEO PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Tuan Ha-Ngoc

	Name:	 	 Tuan Ha-Ngoc

	Its:	 	 President & CEO

 Accepted in Palo Alto, California: 

 

			
	LENDER:
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	By:	 	 /s/ Ben Bang

	Name:	 	 Ben Bang

	Its:	 	 Associate General Counsel

	
	HERCULES CAPITAL FUNDING TRUST 2012-1
		
	By:	 	Hercules Technology Growth Capital, Inc., as Servicer
		
	By:	 	 /s/ Ben Bang

	Name:	 	 Ben Bang

	Its:	 	 Associate General Counsel

	
	 HERCULES TECHNOLOGY III, L.P.,

	a Delaware limited partnership
		
	By:	 	Hercules Technology SBIC Management, LLC, its General Partner
		
	By:	 	Hercules Technology Growth Capital, Inc., its Manager
		
	By:	 	 /s/ Ben Bang

	Name:	 	 Ben Bang

	Its:	 	 Associate General Counsel

 Schedule 1 

EXHIBIT A 
 ADVANCE
REQUEST 
  

											
	To:	  	Lender:	 		  	Date:	  	            , 2014	 	
		  	Hercules Technology Growth Capital, Inc.	 		  		  		 	
		  	Hercules Capital Funding Trust 2012-1	 		  		  		 	
		  	Hercules Technology III, L.P.	 		  		  		 	
		  	400 Hamilton Avenue, Suite 310	 		  		  		 	
		  	 Palo Alto, CA 94301
 Facsimile:
650-473-9194
	 		  		  		 	
		  	Attn: Bryan Jadot	 		  		  		 	

 AVEO Pharmaceuticals, Inc. (“Borrower”) hereby requests from Hercules Technology Growth Capital,
Inc., Hercules Capital Funding Trust 2012-1, and Hercules Technology III, L.P. (collectively, “Lender”) a 2014 Term Loan Advance in the amount of          Dollars
($        ) on             ,          (the “Advance Date”) pursuant to the Loan and Security
Agreement between Borrower and Lender (as amended, the “Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement. 

Please: 
  

									
		 	(a)	  	Issue a check payable to Borrower	 	  
	 	
		 		  	                        or	 		 	
		 	(b)	  	Wire Funds to Borrower’s account	 	  
	 	
		 		  	Bank:	 	  

		 		  	Address:	 	  

		 		  	ABA Number:	 	  

		 		  	Account Number:	 	  

		 		  	Account Name:	 	  

 Borrower represents that the conditions precedent to the 2014 Term Loan Advance set forth in the Agreement are
satisfied and shall be satisfied upon the making of such 2014 Term Loan Advance, including but not limited to: (i) that the representations and warranties set forth in the Agreement are and shall be true and correct in all material respects on
and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date; (ii) that Borrower is in compliance in all material respects
with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (iii) that as of the Advance Date, no fact or condition exists that would (or would, with the passage of time, the giving of notice,
or both) constitute an Event of Default under the Loan Documents. Borrower understands and acknowledges that Lender has the right to review the financial information supporting this representation and, based upon such review in its sole discretion,
Lender may decline to fund the requested 2014 Term Loan Advance. 
 Borrower hereby represents that Borrower’s corporate status and locations have not
changed since the date of the Agreement or, if the Attachment to this Advance Request is completed, are as set forth in the Attachment to this Advance Request. 

Borrower agrees to notify Lender promptly before the funding of the 2014 Term Loan Advance if any of the matters which have been represented
above shall not be true and correct on the Advance Date, and if Lender has received no such notice before the Advance Date then the statements set forth above shall be deemed to have been made and shall be deemed to be true and correct as of the
Advance Date. 
 Executed as of [            ], 2014. 

 

			
	BORROWER:
	
	AVEO PHARMACEUTICALS, INC.
		
	SIGNATURE:	 	  

 
			
	TITLE:	 	  

 
			
	PRINT NAME:	 	  

 ATTACHMENT TO ADVANCE REQUEST 

Dated:                      

Borrower hereby represents and warrants to Lender that Borrower’s current name and organizational status is as follows: 

 

			
	Name:	  	AVEO Pharmaceuticals, Inc.
	Type of organization:	  	Corporation
	State of organization:	  	Delaware
	Organization file number:	  	3444819

 Borrower hereby represents and warrants to Lender that the street addresses, cities, states and postal codes of its current
locations are as follows: 

 Schedule 2 

EXHIBIT B-3 
 2014 TERM
LOAN ADVANCE PROMISSORY NOTE 
  

			
	$[    ],000,000	  	Advance Date:                  , 20[    ]
		  	Maturity Date:                  , 20[    ]

 FOR VALUE RECEIVED, AVEO Pharmaceuticals, Inc., a Delaware corporation, for itself and each of its
Subsidiaries which executes and delivers a Joinder Agreement (the “Borrower”) hereby promises to pay to the order of Hercules Technology Growth Capital, Inc., Hercules Capital Funding Trust 2012-1, Hercules Technology III, L.P, or the
holder of this Note (the “Lender”) at 400 Hamilton Avenue, Suite 310, Palo Alto, CA 94301 or such other place of payment as the holder of this 2014 Term Loan Advance Promissory Note (this “Promissory Note”) may specify from time
to time in writing, in lawful money of the United States of America, the principal amount of [    ] Million Dollars ($[    ],000,000) or such other principal amount as Lender has advanced to Borrower, together
with interest at a floating per annum rate equal to the 2014 Term Loan Interest Rate (as defined in the Loan Agreement (as defined below)). 

This Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Loan and Security Agreement
dated May 28, 2010, by and between Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and security of the
Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof. All payments shall be made in accordance with the Loan Agreement. All terms
defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall constitute a default under this Promissory Note. 

Borrower waives presentment and demand for payment, notice of dishonor, protest and notice of protest under the UCC or any applicable law.
Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory Note has been negotiated and delivered to Lender and is payable in the State of
California. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of California, excluding any conflicts of law rules or principles that would cause the application of the laws of any other
jurisdiction. 
 BORROWER FOR ITSELF AND 
 ON BEHALF OF ITS
SUBSIDIARIES: 
 (if such subsidiary executes and delivers a Joinder Agreement) 

 

			
	AVEO PHARMACEUTICALS, INC.
		
	By:	 	
	Title:	 	

 Schedule 3 

EXHIBIT F 
 COMPLIANCE
CERTIFICATE 
 Hercules Technology Growth Capital, Inc. 

Hercules Capital Funding Trust 2012-1 
 Hercules Technology III,
L.P. 
 400 Hamilton Avenue, Suite 310 
 Palo Alto, CA 94301

 Facsimile: 650-473-9194 
 Attn: Bryan Jadot 

Reference is made to that certain Loan and Security Agreement dated May 28, 2010 and all ancillary documents entered into in connection with such Loan
and Security Agreement all as may be amended from time to time, (hereinafter referred to collectively as the “Loan Agreement”) between Hercules Technology Growth Capital, Inc., Hercules Capital Funding Trust 2012-1, and Hercules Technology
III, L.P. (collectively, the “Lender”) on the one hand, and AVEO Pharmaceuticals, Inc. (the “Company”) as Borrower, on the other hand. All capitalized terms not defined herein shall have the same meaning as defined in the Loan
Agreement. 
 The undersigned is an Officer of the Borrower, knowledgeable of all Borrower financial matters, and is authorized to provide certification of
information regarding the Borrower; hereby certifies, in such capacity as set forth below, that as of the date hereof and in accordance with the terms and conditions of the Loan Agreement, the Borrower is in compliance in all material respects for
the period ending                      of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained
therein are true and correct on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving
effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties. Attached are the required documents supporting the above certification. The undersigned further certifies, in such
capacity as set forth below, that these are prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statement and subject to normal year-end adjustments) and are consistent from one period to the
next except as explained below. 
  

					
	REPORTING REQUIREMENT	  	REQUIRED	 	CHECK IF ATTACHED
			
	Interim Financial Statements	  	Monthly within 30 days	 	            
			
	Interim Financial Statements	  	Quarterly within 30 days	 	            
			
	Audited Financial Statements	  	FYE within 90 days	 	            
			
	Intellectual Property on Exhibit D	  	Quarterly within 30 days	 	            

  

							
	FINANCIAL COVENANT	  	REQUIRED	  	ACTUAL	  	COMPLIES (YES/NO)
				
	Liquidity Ratio	  	1.25:1.00	  	            	  	            

  

			
	Very Truly Yours,
	
	AVEO PHARMACEUTICALS, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Its:EX-10.2

 Exhibit 10.2 

THE WARRANT PROVIDED FOR IN THIS AGREEMENT AND THE SECURITIES ISSUABLE UPON EXERCISE OF SUCH WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT
AGREEMENT 
 To Purchase Shares of Common Stock of 

AVEO PHARMACEUTICALS, INC. 
 Dated
as of September 24, 2014 (the “Effective Date”) 
 WHEREAS, AVEO Pharmaceuticals, Inc., a Delaware corporation (the
“Company”) and Hercules Technology II, L.P., a Delaware limited partnership and Hercules Technology III, L.P., a Delaware limited partnership (the “Warrantholder”) are parties to a certain Loan and Security
Agreement, dated as of May 28, 2010, as amended by that certain Amendment No. 1 to Loan and Security Agreement, dated as of December 21, 2011, and as further amended by that certain Amendment No. 2 to Loan and Security Agreement,
dated as of March 31, 2012 (together referred to herein as the “Original Loan Agreement”); 
 WHEREAS, Hercules
Technology II, L.P. has assigned its rights and obligations as a lender in the Original Loan Agreement to Hercules Technology Growth Capital, Inc., a Maryland corporation and the Company has entered into an Amendment No. 3 to the Loan and
Security Agreement dated as of the date hereof (the “Amendment to the Loan Agreement”) with Hercules Technology Growth Capital, Inc. and the Warrantholder (the Original Loan Agreement as amended by the Amendment to the Loan
Agreement is referred to herein as the “Loan Agreement”); 
 WHEREAS, the Company desires to grant to Warrantholder, in
consideration for, among other things, the financial accommodations provided for in the Amendment to the Loan Agreement, the right to purchase shares of its Common Stock (as defined below), pursuant to this Warrant Agreement (the
“Agreement”); 

  
 1 

 NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan Agreement
and providing the financial accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 

SECTION 1. GRANT OF THE RIGHT TO PURCHASE COMMON STOCK. 

For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the
conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to 608,696 fully paid and non-assessable shares of the Common Stock (as defined below) at the Exercise Price (as defined below) effective upon the Effective Date.
As used herein, the following terms shall have the following meanings: 
 “1934 Act” has the meaning given to it in
Section 10(d). 
 “Acknowledgment of Exercise” has the meaning given to it in Section 3(a). 

“Act” means the Securities Act of 1933, as amended. 

“Amendment to the Loan Agreement” has the meaning given to it in the preamble to this Agreement. 

“Agreement” has the meaning given to it in the preamble to this Agreement. 

“Charter” means the Company’s Certificate of Incorporation or other constitutional document, as the same may be amended
and/or restated from time to time. 
 “Claims” has the meaning given to it in Section 12(p). 

“Common Stock” means the Company’s common stock, $.001 par value per share. 

“Company” has the meaning given to it in the preamble to this Agreement. 

“Effective Date” has the meaning given to it in the preamble to this Agreement. 

“Exercise Price” means $1.15. 

“Lender” has the meaning given to it in the Loan Agreement. 

“Loan Agreement” has the meaning given to it in the preamble to this Agreement. 

“Merger Event” means a merger or consolidation involving the Company in which (x) the Company is not the surviving
entity, or (y) the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of capital of another entity. 

“Net Issuance” has the meaning given to it in Section 3(a). “Notice of Exercise” has the meaning given to it in
Section 3(a). 
 “Original Loan Agreement” has the meaning given to it in the preamble to this Agreement. 

  
 2 

 “Purchase Price” means, with respect to any exercise of the Warrant provided for
in this Agreement, an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of Common Stock to be acquired under this Agreement pursuant to such exercise. 

“Registration Statement” has the meaning given to it in Section 9(k). 

“Rules” has the meaning given to it in Section 12(q). 

“SEC” means the Securities and Exchange Commission. 

“Transfer Notice” has the meaning given to it in Section 11. 

“Warrant” has the meaning given to it in Section 2. 

“Warrant Term” has the meaning given to it in Section 2. 

“Warrantholder” has the meaning given to it in the preamble to this Agreement. 

In addition, capitalized terms used herein but not otherwise defined herein shall have the meaning assigned to such terms in the Loan Agreement. 

SECTION 2. TERM OF THE AGREEMENT. 

Except as otherwise provided for herein, the term of this Agreement (the “Warrant Term”) and the right to purchase Common
Stock as granted herein (the “Warrant”) shall commence on the Effective Date and shall be exercisable for a period ending five (5) years from the Effective Date. 

SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time,
or from time to time, during the Warrant Term, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly completed and executed.
Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than three (3) business days thereafter, the Company shall issue to the Warrantholder a
certificate for the number of shares of Common Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares
which remain subject to future purchases, if any. 
 The Purchase Price may be paid at the Warrantholder’s election either (i) by
cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Common Stock to be exercised under this Agreement and, if applicable, an amended Agreement representing the remaining number of shares purchasable hereunder,
as determined below (“Net Issuance”). If the Warrantholder elects the Net Issuance method, the Company will issue Common Stock in accordance with the following formula: 

 

							
		  		 	 X = Y(A-B)
	  	
		  		 	            A	  	

  
 3 

					
	Where:	  	X	  	the number of shares of Common Stock to be issued to the Warrantholder.
			
		  		  	Y = the number of shares of Common Stock requested to be exercised under this Agreement (including the number of shares to be cancelled in payment of the Purchase Price).
			
		  		  	A = the fair market value of one (1) share of Common Stock at the time of issuance of such shares of Common Stock.
			
		  	B =	  	the Exercise Price.

 For purposes of the above calculation, the fair market value per share of Common Stock shall mean: 

(i) if the Common Stock is traded on the New York Stock Exchange, the American Stock Exchange, any exchange operated by The
NASDAQ Stock Market LLC or any other securities exchange, the fair market value shall be deemed to be the average of the closing prices over a five (5) day period ending three (3) days before the day the fair market value of the Common
Stock is being determined; or 
 (ii) if at any time the Common Stock is not listed on the New York Stock Exchange, the
American Stock Exchange, any exchange operated by The NASDAQ Stock Market LLC or any other securities exchange, the fair market value of such Common Stock shall be fair market value of Common Stock as determined in good faith by the Company’s
Board of Directors (provided, that if Warrantholder disagrees with the fair market value determined by the Company’s Board of Directors Warrantholder may solicit, from an appraiser reasonably acceptable to the Company, an independent appraisal
of the fair market value of the Common Stock and, if such valuation is higher, Warrantholder may substitute the Board of Directors’ fair market value determination with that of the independent appraiser), unless the Company shall consummate a
Merger Event pursuant to which the Company is not the surviving party, in which case the fair market value of Common Stock shall be deemed to be the per share value received by the holders of the Company’s Common Stock on a Common
Stock-equivalent basis pursuant to such Merger Event. 
 Upon partial exercise by either cash or Net Issuance, the Company shall promptly
issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective Date
hereof. 
 (b) Exercise Prior to Expiration. To the extent that the Warrantholder has not exercised its purchase rights under this
Agreement to all Common Stock subject hereto, and if the fair market value of one share of the Common Stock is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically exercised pursuant to Section 3(a) (even
if not surrendered) immediately before the expiration of the Warrant Term. For purposes of such 

  
 4 

 
automatic exercise, the fair market value of one share of the Common Stock upon such expiration shall be determined pursuant to Section 3(a). To the extent this Agreement or any portion
thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Common Stock, if any, the Warrantholder is to receive by reason of such automatic
exercise. 
 SECTION 4. RESERVATION OF SHARES. 

From and after the Effective Date, the Company will at all times have authorized and reserved a sufficient number of shares of its Common
Stock to provide for the exercise of the rights to purchase Common Stock as provided for herein. 
 SECTION 5. NO FRACTIONAL SHARES
OR SCRIP. 
 No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the Warrant provided for in
this Agreement, but in lieu of such fractional shares the Company shall make a cash payment therefor upon the basis of the fair market value of the share, as determined in accordance with Section 3. 

SECTION 6. NO RIGHTS AS SHAREHOLDER/STOCKHOLDER. 

This Agreement does not entitle the Warrantholder to any voting rights or other rights as a shareholder/stockholder of the Company prior to
the exercise of the Warrant. 
 SECTION 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of the Warrant. Warrantholder’s initial
address, for purposes of such registry, is set forth in Section 12(g). Warrantholder may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 

The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment, as follows: 

(a) Merger Event. If at any time there shall be a Merger Event, then, as a part of such Merger Event, lawful provision shall be made so
that the Warrantholder shall thereafter be entitled to receive, upon exercise of the Warrant, the kind, amount and value of shares of common stock or other securities or property of the successor, surviving or purchasing corporation resulting from,
or participating in, such Merger Event that would have been issuable if Warrantholder had exercised the Warrant immediately prior to the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board
of Directors) shall be made in the application of the provisions of this Agreement with respect to the rights and interests of the Warrantholder after the Merger Event to the end that the provisions of this Agreement (including adjustments of the
Exercise Price) shall be applicable in their entirety, and to the greatest extent possible. Without limiting the foregoing, in connection with any Merger Event, upon the closing thereof, the successor, surviving or purchasing entity shall assume the

  
 5 

 
obligations of this Agreement. The provisions of this Section 8(a) shall similarly apply to successive Merger Events. In connection with a Merger Event and upon Warrantholder’s written
election to the Company, the Company shall cause the Warrant to be exchanged for the consideration that Warrantholder would have received if Warrantholder chose to exercise its right to have shares issued pursuant to the Net Issuance provisions of
this Agreement without actually exercising such right, acquiring such shares and exchanging such shares for such consideration. 
 (b)
Reclassification of Shares. Except as set forth in Section 8, if the Company at any time shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase
rights under this Agreement exist into the same or a different number of securities of any other class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the
result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. 

(c) Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its Common Stock purchasable hereunder,
(i) in the case of a subdivision, the Exercise Price shall be proportionately decreased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased. 

(d) Stock Dividends. If the Company at any time while the Warrant is outstanding and unexpired shall: 

(i) pay a dividend with respect to the Common Stock payable in Common Stock, then the Exercise Price shall be adjusted, from
and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction (A) the
numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of Common Stock outstanding immediately
after such dividend or distribution; or 
 (ii) make any other distribution with respect to the Common Stock, except any
distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise of the Warrant a proportionate share of any
such distribution as though it were the holder of the Common Stock as of the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution. 

(e) Antidilution Rights. Antidilution rights applicable to the Common Stock purchasable hereunder, if any, are as set forth in the
Charter. The Company shall promptly provide the Warrantholder with a copy of any restatement, amendment, modification or waiver of the Charter; provided, that no such restatement, amendment, modification or waiver shall impair or reduce the
antidilution rights, if any, applicable to the Common Stock unless such restatement, amendment, modification or waiver affects the rights of Warrantholder with respect 

  
 6 

 
to the Common Stock purchasable hereunder in the same manner as it affects all other holders of the Common Stock. The Company shall, within ten (10) business days of the end of each fiscal
quarter following the Effective Date in which an antidilution adjustment with respect to the Common Stock purchasable hereunder occurred pursuant to the Charter, provide Warrantholder with written notice of any issuance of its stock or other equity
security during such fiscal quarter that triggered such an antidilution adjustment, which notice shall include (a) the price at which such stock or security was sold, (b) the number of shares issued, and (c) such other information as
reasonably necessary for Warrantholder to verify that such antidilution adjustment occurred and the amount of any such adjustment. For the avoidance of doubt, there shall be no duplicate antidilution adjustment pursuant to this subsection (e), the
forgoing subsection (d) and the Charter. 
 (f) Notice of Adjustments. If (i) the Company shall declare any dividend or
distribution upon its Common Stock, whether in stock, cash, property or other securities (assuming Warrantholder consents to a dividend involving cash, property or other securities under the Loan Agreement, if such consent is then required by the
terms of the Loan Agreement); (ii) the Company shall offer for subscription pro rata to the holders of Common Stock any additional shares of stock of any class or other rights; (iii) there shall be any Merger Event or the Company shall
sell, lease, license or otherwise transfer all or substantially all of its assets; or (iv) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall send to
the Warrantholder: (A) at least fifteen (15) days’ prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend, distribution, subscription rights (specifying the date on
which the holders of Common Stock shall be entitled thereto) or for determining rights to vote in respect of such Merger Event, dissolution, liquidation or winding up; and (B) in the case of any such Merger Event, sale, lease, license or other
transfer of all or substantially all of the Company’s assets, dissolution, liquidation or winding up, at least fifteen (15) days’ prior written notice of the date when the same shall take place (and specifying the date on which the
holders of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon such Merger Event, dissolution, liquidation or winding up). 

Each such written notice shall set forth, in reasonable detail, (i) the event requiring the notice, and (ii) if any adjustment is
required to be made, (A) the amount of such adjustment, (B) the method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and (D) the number of shares subject to
purchase hereunder after giving effect to such adjustment, and shall only be provided in the manner set forth in Section 12(g)(i). 

(g) Timely Notice. Failure to timely provide such notice required by subsection (f) above shall entitle Warrantholder to retain
the benefit of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by Warrantholder. 

  
 7 

 SECTION 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

(a) Reservation of Common Stock. The Common Stock issuable upon exercise of the Warrantholder’s rights has been, or in accordance
with Section 4, will be duly and validly reserved and, when issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any
nature whatsoever; provided, that the Common Stock issuable pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws or in this Agreement. The Company has made available to the Warrantholder
true, correct and complete copies of its Charter and current bylaws. The issuance of certificates for shares of Common Stock upon exercise of the Warrant and payment of the Purchase Price shall be made without charge to the Warrantholder for any
issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of Common Stock; provided, that the Company shall not be required to pay any tax which may be payable in
respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder. 
 (b) Due
Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Common Stock, have been duly
authorized by all necessary corporate action on the part of the Company. The execution and delivery by the Company of this Agreement: (1) does not violate the Company’s Charter or current bylaws; (2) does not contravene any law or
governmental rule, regulation or order applicable to it; and (3) does not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by which it is
bound. This Agreement constitutes the legal, valid and binding agreement of the Company, enforceable in accordance with its terms. 
 (c)
Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of, any state, federal or other governmental authority or agency is required on the part of the Company with
respect to the execution, delivery and performance by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which
filings will be made by the time required thereby. 
 (d) Issued Securities. All issued and outstanding shares of Common Stock have
been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock and any other outstanding securities were issued in full compliance with all federal and state securities laws. In addition, as of
the date hereof in the case of each of clause (i) and clause (ii) below and as of the date immediately preceding the Effective Date in the case of clause (iii) below: 

(i) The authorized capital stock of the Company consists of (A) 100,000,000 shares of Common Stock, of which 52,264,026
shares are issued and outstanding, and (B) 5,000,000 shares of Preferred Stock, $0.001 par value per share, none of which are issued or outstanding. 

(ii) The Company has reserved 8,500,000 shares of Common Stock for issuance under its stock incentive plan(s), under which
options to purchase 5,913,276 

  
 8 

 
shares of Common Stock are outstanding. Other than the options referred to in the prior sentence, there are no other options, warrants, conversion privileges or other rights presently outstanding
to purchase or otherwise acquire any authorized but unissued shares of the Company’s capital stock or other securities of the Company. 

(iii) Pursuant to the Company’s Charter, no stockholder of the Company has preemptive rights to purchase new issuances of
the Company’s capital stock that have not been properly waived in connection with the issuance of the Warrant or the Common Stock to be issued upon the exercise of the Warrant. 

(e) Insurance. The Company has in full force and effect insurance policies, with extended coverage, insuring the Company and its
property and business against such losses and risks, and in such amounts, as are customary for corporations engaged in a similar business and similarly situated and as otherwise may be required pursuant to the terms of any other contract or
agreement. 
 (f) Other Commitments to Register Securities. Except as set forth in this Agreement and the Fourth Amended and Restated
Investor Rights Agreement dated as of March 18, 2009, as amended, by and among the Company and the other parties thereto, there is no agreement between the Company and any holders of its securities under which the Company has any obligation to
register under the Act any of its presently outstanding securities or any of its securities which may hereafter be issued. 
 (g) Exempt
Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance of the Common Stock upon exercise of the Warrant will constitute a transaction exempt from (i) the registration requirements
of the Act and (ii) the qualification requirements of the applicable state securities laws. 
 (h) Compliance with Rule 144. If
the Warrantholder proposes to sell Common Stock issuable upon the exercise of this Agreement in compliance with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the Company, the Company shall furnish to the
Warrantholder, within ten days after receipt of such request, a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time. 

(i) Information Rights. During the Warrant Term, Warrantholder shall be entitled to the information rights contained in
Section 7.1 of the Loan Agreement, and Section 7.1 of the Loan Agreement is hereby incorporated into this Agreement by this reference as though fully set forth herein, provided, however, that the Company shall not be required to deliver a
Compliance Certificate once all Indebtedness (as defined in the Loan Agreement) owed by the Company to Warrantholder has been repaid. 
 (j)
Listing of Shares. The Common Stock is listed for trading on The NASDAQ Global Market as of the Effective Date and the Company shall maintain such listing through the Warrant Term. 

(k) Registration Rights. If, prior to the date on which Warrantholder may sell all shares of Common Stock issuable upon exercise
of this Warrant without restriction pursuant to 

  
 9 

 
Rule 144 promulgated under the Act (assuming that Warrantholder were to exercise this Warrant by Net Issuance), the Company proposes to register under the Act for resale any shares of Common
Stock held by any person (other than the Company) (other than a registration statement on Form S-8 or its successor or any other form for a similar limited purpose), then the Company shall give Warrantholder reasonable prior written notice of such
proposed registration and shall, upon written request of the Warrantholder given within five days after the Company provides such notice, permit Warrantholder to include (but Warrantholder shall not be obligated to include) all or a portion (as
determined by Warrantholder in its sole discretion) of the shares of Common Stock issuable upon exercise of this Warrant (exclusive of any shares of Common Stock theretofore registered pursuant to the provisions of this Section 9(k)) in such
registration on a pari passu basis with the other holders participating therein and on the same terms and conditions as applicable to such other holders; provided that the Company will have the right to postpone or withdraw any such registration
without obligation to the Warrantholder. 
 SECTION 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder: 

(a) Investment Purpose. The right to acquire Common Stock or the Common Stock issuable upon exercise of the Warrantholder’s rights
contained herein has been, and such shares will be, acquired for investment and not with a view to, or for sale in connection with, the distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in, or
any agreement, undertaking or commitment with respect to, any public distribution of the same. 
 (b) Private Issue. The
Warrantholder understands (i) that the Common Stock issuable upon exercise of this Agreement is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will
be exempt from the registration and qualifications requirements thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 

(c) Financial Risk. The Warrantholder has sufficient knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment, in the Company. Such Warrantholder has made detailed inquiry concerning the Company, its business and its personnel and the officers
of the Company have made available to such Warrantholder any and all written information which it has requested and have answered to such Warrantholder’s satisfaction all inquiries made by such Warrantholder. 

(d) Risk of No Registration. Without prejudice to Section 9(k), the Warrantholder understands that if the Company does not
register shares of its capital stock with the SEC pursuant to Section 12 of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement
covering shares of its capital stock under the Act covering the Warrant granted pursuant to this Agreement and the shares of Common Stock issuable upon exercise of the Warrant granted pursuant to this

  
 10 

 
Agreement is not in effect when it desires to sell (i) the Warrant granted pursuant to this Agreement or (ii) the shares of Common Stock issuable upon exercise of such Warrant, it may
be required to hold such securities for an indefinite period. The Warrantholder also understands that any sale of (A) such Warrant or (B) the shares of Common Stock issued or issuable hereunder which might be made by it in reliance upon
Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule. 
 (e) Accredited Investor.
Warrantholder is an “accredited investor” within the meaning of Rule 501 of Regulation D, as presently in effect, under the Act. 

(f) No Short Sales. The Warrantholder has not engaged, and will not engage, in “short sales” of the Common Stock of the
Company. The term “short sale” shall mean any sale of a security which the seller does not own or any sale which is consummated by the delivery of a security borrowed by, or for the account of, the seller. 

SECTION 11. TRANSFERS. 

Subject to compliance with the provisions of this Agreement and applicable federal and state securities laws, this Agreement and all rights
hereunder are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Subject to such compliance, each taker and holder of this Agreement, by taking or
holding the same, consents and agrees that this Agreement, when endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall
be treated by the Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be
recorded on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and
other governmental charges imposed on such transfer. Until the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. 

Each certificate representing shares acquired upon exercise of such Warrant shall bear a legend substantially in the following form: 

“The securities represented by this certificate have not been registered under the Securities Act of 1933, as amended, and may not be
offered, sold or otherwise transferred, pledged or hypothecated unless and until such securities are registered under such Act or an opinion of counsel satisfactory to the Company is obtained to the effect that such registration is not
required.” 
 SECTION 12. MISCELLANEOUS. 

(a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been
executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company. 

  
 11 

 (b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed
to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where the
non-defaulting party will not have an adequate remedy at law and where damages will not be readily ascertainable. Each party hereto expressly agrees that it shall not oppose an application by the other party or any other person entitled to the
benefit of this Agreement requiring specific performance of any or all provisions hereof or enjoining a party from continuing to commit any such breach of this Agreement. 

(c) No Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the
observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the rights
of the Warrantholder against impairment. 
 (d) Additional Documents. The Company shall supply such other documents as the
Warrantholder may from time to time reasonably request. 
 (e) Attorney’s Fees. In any litigation, arbitration or court
proceeding between the Company and the Warrantholder relating hereto, the prevailing party shall be entitled to reasonable attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this
Section 12(e), attorneys’ fees shall include without limitation fees incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in
connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any
judgment. 
 (f) Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid,
illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to
the intention of the parties underlying the invalid, illegal or unenforceable provision. 
 (g) Notices. Except as otherwise provided
herein, any notice, demand, request, consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and
shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the first business day after transmission by facsimile or hand delivery or deposit with an overnight express service or overnight mail delivery
service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, and shall be addressed to the party to be notified as follows: 

If to Warrantholder: 
 HERCULES
TECHNOLOGY III, L.P. 
 Legal Department 

Attention: Chief Legal Officer and Manuel Henriquez 

400 Hamilton Avenue, Suite 310 

Palo Alto, CA 94301 
 Facsimile:
650-473-9194 
 Telephone: 650-289-3060 

  
 12 

 With a copy to: 

RIEMER & BRAUNSTEIN LLP 

Attn: Adam W. Jacobs 
 Three
Center Plaza, 6th Floor 
 Boston, Massachusetts 02108 

Facsimile: 617-880-3456 

Telephone: 617-880-3513 
 (i) If
to the Company: 
 AVEO PHARMACEUTICALS, INC. 

Attention: Tuan Ha-Ngoc, President and Chief Executive Officer 

650 E. Kendall Street 
 Cambridge,
MA 02412 
 Facsimile: 617-995-4995 

Telephone: 617-299-5000 
 With a
copy to: Joseph Vittiglio, Esquire, General Counsel 
 With a copy to: 

WILMER CUTLER PICKERING HALE AND DORR LLP. 

Attention: Steven D. Singer, Esq. 

60 State Street 
 Boston, MA 02109

 Facsimile: 617-526-5000 

Telephone: 617-526-6000 
 or to such other
address as each party may designate for itself by like notice. 
 (h) Entire Agreement; Amendments. This Agreement constitutes the
entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written
or oral, with respect to the subject matter hereof (including the proposal letter dated June 25, 2014 between the Warrantholder and the Company). None of the terms of this Agreement may be amended except by an instrument executed by each of the
parties hereto. 

  
 13 

 (i) Headings. The various headings in this Agreement are inserted for convenience only and
shall not affect the meaning or interpretation of this Agreement or any provisions hereof. 
 (j) Advice of Counsel. Each of the
parties represents to each other party hereto that it has discussed (or had an opportunity to discuss) with its counsel this Agreement and, specifically, the provisions of Sections 12(n), 12(o), 12(p), 12(q) and 12(r). 

(k) No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the
authorship of any provisions of this Agreement. 
 (l) No Waiver. No omission or delay by either party at any time to enforce any
right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the other party at any time designated, shall be a waiver of any such right or remedy to which such party is entitled, nor shall it in
any way affect the right of such party to enforce such provisions thereafter. 
 (m) Survival. All agreements, representations and
warranties contained in this Agreement or in any document delivered pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement.

 (n) Governing Law. This Agreement has been negotiated and delivered to Warrantholder in the State of California, and shall have
been accepted by Warrantholder in the State of California. Delivery of Common Stock to Warrantholder by the Company under this Agreement is due in the State of California. This Agreement shall be governed by, and construed and enforced in accordance
with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

(o) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any
state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in San Mateo County, State
of California; (b) waives any objection as to jurisdiction or venue in San Mateo County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably
agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements
for notice set forth in Section 12(g), and shall be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either
party to bring proceedings in the courts of any other jurisdiction. 

  
 14 

 (p) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex
financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved
by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY,
“CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons other than the Company
and Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind,
arising out of this Agreement. 
 (q) Arbitration. If the Mutual Waiver of Jury Trial set forth in Section 12(p) is ineffective
or unenforceable, the parties agree that all Claims shall be submitted to binding arbitration in accordance with the commercial arbitration rules of JAMS (the “Rules”), such arbitration to occur before one arbitrator, which arbitrator
shall be a retired California state judge or a retired Federal court judge. Such proceeding shall be conducted in California with California rules of evidence and discovery applicable to such arbitration. The decision of the arbitrator shall be
binding on the parties, and shall be final and non-appealable to the maximum extent permitted by law. Any judgment rendered by the arbitrator may be entered in a court of competent jurisdiction and enforced by the prevailing party as a final
judgment of such court. 
 (r) Prearbitration Relief. In the event Claims are to be resolved by arbitration, either party may seek
from a court of competent jurisdiction identified in Section 12(o), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all
Claims are otherwise subject to resolution by binding arbitration. 
 (s) Counterparts. This Agreement and any amendments, waivers,
consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but
one and the same instrument. 
 (t) Specific Performance. The parties hereto hereby declare that it is impossible to measure in money
the damages which will accrue to a party hereto by reason of the other party’s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically enforceable by either party hereto.
If a party hereto institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense therein that such party has an adequate remedy at
law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 

[Remainder of Page Intentionally Left Blank] 

  
 15 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its officers thereunto duly
authorized as of the Effective Date. 
  

									
		 	COMPANY:	 		 	AVEO PHARMACEUTICALS, INC.
					
		 		 		 	By:	 	 /s/ Tuan Ha-Ngoc

		 		 		 	Name:	 	 Tuan Ha-Ngoc

		 		 		 	Title:	 	 President and CEO

				
		 	WARRANTHOLDER:	 		 	HERCULES TECHNOLOGY III, L.P.,
		 		 		 	a Delaware limited partnership
					
		 		 		 	By:	 	Hercules Technology SBIC Management, LLC, its General Partner
					
		 		 		 	By:	 	Hercules Technology Growth Capital, Inc., its Manager
					
		 		 		 	By:	 	 /s/ Ben Bang

		 		 		 	Name:	 	 Ben Bang

		 		 		 	Its:	 	 Senior Counsel

  
 16 

 EXHIBIT I 

NOTICE OF EXERCISE 
  

	To:	AVEO Pharmaceuticals, Inc. (the “Company”) 

  

	 	(1)	The undersigned Warrantholder hereby elects to purchase [                ] shares of the
[                ] Common Stock of the Company, pursuant to the terms of that certain Warrant Agreement, dated as of September 24, 2014, between the Company and the
Warrantholder (the “Agreement”), and [CASH PAYMENT: tenders herewith payment of the Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement
to effect a Net Issuance.] 

  

	 	(2)	In exercising its rights to purchase the [                ] Common Stock of the Company, the undersigned, as representative for the
Warrantholder, hereby confirms and acknowledges the investment representations and warranties made in Section 10 of the Agreement. 

  

	 	(3)	Please issue a certificate or certificates representing said shares of [                ] Common Stock in the name of the Warrantholder or
in such other name as is specified below. 

  

									
		 	WARRANTHOLDER:	 		 	HERCULES TECHNOLOGY III, L.P.,
		 		 		 	a Delaware limited partnership
					
		 		 		 	By:	 	Hercules Technology SBIC Management, LLC, its General Partner
					
		 		 		 	By:	 	Hercules Technology Growth Capital, Inc., its Manager
					
		 		 		 	By:	 	  

		 		 		 	Name:	 	  

		 		 		 	Its:	 	  

				
		 		 		 	Address:
					
		 		 		 		 	 400 Hamilton Avenue, Suite 310
 Palo Alto, CA
94301
 Facsimile: 650-473-9194
 Telephone:
650-289-3060

  
 17 

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 
 The undersigned, as
representative of AVEO Pharmaceuticals, Inc. (the “Company”), hereby acknowledges receipt of the “Notice of Exercise” from Hercules Technology III, L.P. (the “Warrantholder”), to purchase
[                ] shares of the Common Stock of the Company, pursuant to the terms of that certain Warrant Agreement, dated as of
[            ], 2014, between the Company and the Warrantholder (the “Agreement”), and further acknowledges that shares remain subject to purchase under the terms of the
Agreement. 
  

					
	 COMPANY:
	 	AVEO PHARMACEUTICALS, INC.
			
		 	By:	 	  

			
		 	Title:	 	  

			
		 	Date:	 	  

  
 18 

 EXHIBIT III 

TRANSFER NOTICE 
 FOR VALUE RECEIVED, that
certain Warrant Agreement, dated as of             , 2014, between AVEO Pharmaceuticals, Inc. and Hercules Technology III, L.P., a Delaware limited partnership, as the Warrantholder (the
“Agreement”), and all rights evidenced thereby are hereby transferred and assigned to 
  

			
	  

	(Please Print) whose address is	 	  

	
	  

  

			
	Dated:	 	  

 
			
		
	Holder’s Signature:	 	  

		
	Holder’s Address:	 	  

	
	  

 Signature Guaranteed: 

			
	  
	  	

 The signature should be guaranteed by an eligible guarantor institution (banks, stockbrokers, savings and loan associations
and credit unions with membership in an approved signature guarantee medallion program) pursuant to Rule 17Ad-15 under the Securities Exchange Act of 1934. 

NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without alteration or enlargement or any
change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. 

  
 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]